AVEO Oncology

Biotechnology ResearchMassachusetts, United States201-500 Employees

AVEO Oncology is a mid-sized biotechnology company focused on cancer therapeutics. In the United States, it markets FOTIVDA (tivozanib) for adults with relapsed or refractory renal cell carcinoma who have received two or more prior systemic therapies, illustrating its role in expanding treatment options for kidney cancer. The firm is pursuing ongoing clinical development around FOTIVDA in immuno-oncology combinations for RCC and other indications, along with additional investigational programs.

Headquartered in Boston, Massachusetts, AVEO operates within the biotechnology sector and is described as part of LG Chem. The company emphasizes diversity, equity and inclusion in its workforce. In its latest activity, AVEO announced that two abstracts were accepted for poster presentations at the ASCO 2026 annual meeting, reflecting continued scientific engagement.

Sign up for free to view info

Email Format Employee directory